International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 1 Jan-Feb 2024, pp: 1881-1886 www.ijprajournal.com ISSN: 2249-7781

Areview Article on Lithium Induced Hypothyroidism

Posina Padmasri[1], Rajini SudiReddy[2], S Tirupati Mahalakshmi[3], V Vani [4], K Jahnavi Reddy [5]

[1,3,4,5] *Pharm D Students,Department of Pharmacy Practice*
[2]*Professor, Department of Pharmacy Practice*
Head of the Institute Dr.M.Prasad Rao M.Pharm,Ph.D
M.A.M College of Pharmacy, Kesanupalli, Narasaraopet (522601) Palanadudistrict, AP

Submitted: 20-02-2024 Accepted: 03-03-2024

ABSTRACT
Lithium carbonate a medication known for over 100 years, has been effectively utilized as a psychiatricmedicine. It is normally utilized drug use in the management of unipolar and bipolar depression, acute mania and prophylaxis of bipolar depression. The impact of lithium on the thyroid organ is one of the vital secondary effects in the drawn-out utilization of lithium. lithium as a state of mood stabilizing drug has a complicated mechanism of action. In light of the dynamic vehicle of sodium/iodine particles, lithium despite its concentration gradient, is collected in the thyroid gland at a concentration 3 to 4 times higher than that the plasma. (its organization brings about diminished creation with release inhibition of thyroid chemicals, changing the immune process of the gland) the most normal thyroid side effectsassociated with long term use of lithium treatment areGoitre and Hypothyroidism. It very well may be restrain the arrangement of colloid in thyrocytes, changes the construction of thyroglobulin, debilitate the iodination of tyrosine and disturb theircoupling. In expansion it decreases the clearance of free thyroxine in the serum, thereby in a roundabout way diminishing the action of 5-deiodinase type 1 & 2 and lessening the deiodination of these hormones in liver.

Key words: Lithium carbonate,bipolar disorder, Mania, Goitre, Hypothyroidism

I. INTRODUCTION

John Frederick Joseph Cade, an Australian therapist, firstused lithium to treat patients with hyper episodes of bipolardisorder (BD) in 1949 (1). Strangely, the Danish doctor EricLange involved it in as soon as the nineteenth 100 years in patients withrecurrent burdensome problems (2). Until now, lithium carbonium (as the original normothymic drug) is one of the principal drugsused in psychiatry, and it is still effectively controlled topatients with hyper episodes of BD, to forestall the repeat ofBD, to decrease the seriousness and rate of resulting episodesof mania in patients with a background marked by maniacal conditions, and toprevent the event of depressive episodes in patients withrecurrent depressive problems (3, 4). Besides, a new studyby Tondo et al. uncovered significant decrease of the gamble of suicideduring long haul lithium treatment (5). Lithiumcarbonium has a complex but unclearmechanism of activity, prompting many secondary effects, particularlydisorders of the thyroid organ, the most incessant of whichinclude hypothyroidism and goiter (6-8)

General pharmacological highlights of lithium

Lithium is a soluble base metal which is accessible primarily as lithium carbonate and citrate in quick and supported discharge arrangements. It arrives at top plasma fixations in 1-2 and 4-5 hours for the prompt and supported discharge details separately with a disposal half existence of 18-36 hours. Its discharge is essentially through the kidneys and this renal freedom diminishes with expanding age (9).

The exact systems by which lithium applies its temperament balancing out impacts are as yet not extremely evident. Its neurotropic impacts are somewhat made sense of by the inhibitory impact on the N-methyl D-aspartate receptor that intercedes cell calcium inundation and the concealment of enactment of supportive of apoptotic calcium subordinate flagging pathways (10). Lithium likewise modifies arrival of synapses and reduces glutaminergic action (11).

Effects of lithium on the physiology of the thyroid organ

Different impacts of lithium on the physiology of the thyroid organ have been broadly examined. Lithium has been demonstrated to be

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 1 Jan-Feb 2024, pp: 1881-1886 www.ijprajournal.com ISSN: 2249-7781

profoundly amassed in thyroid cells. In-vivo and vitro concentrates on in rodents have shown that lithium diminishes the take-up of radioiodine into rodent thyroid and salivary organs. In people, lithium organization might result in either diminished or expanded thyroidal radioiodine take-up. A few components are remembered to make sense of this double impact among people. Low thyroid iodine take-up could be because of lithium initiated iodide maintenance and rivalry for the iodide transport inside the thyroid organ. An expansion in the take-up could be interceded by the expanded discharge of thyroid invigorating chemical (TSH) following lithium prompted hypothyroidism (12).

One more key impact of lithium on thyroid organ working happens at the degree of chemical union and delivery. Lithium represses amalgamation and arrival of thyroid chemicals. This inhibitory impact is because of the modification in the tubulin polymerisation and hindrance of the activity of TSH on cyclic adenosine mono phosphate (c-AMP). Lithium additionally changes the construction of thyroglobulin accordingly influencing protein conformity and capability with ensuing iodotyrosine coupling deserts. Lithium organization is related with diminished hepatic deiodination and leeway of free thyroxine (T4). The last option prompts a diminishing in the movement of type I 5' de-iodinase chemical (13,14).

Lithium as a state of mood stabilizing out drug has acomplex instrument of activity. In view of the dynamic vehicle of Na+/I-particles, lithium, notwithstanding its focus slope, isaccumulated in the thyroid organ at a fixation 3 - 4 times higher than that in the plasma. It can restrain the arrangement ofcolloid in thyrocytes, change the design of thyroglobulin, debilitate the iodination of tyrosine's, and upset their coupling.In expansion, it diminishes the leeway of free thyroxine in the serum, subsequently by implication decreasing the action of 5-deiodinasetype 1 and 2 and lessening the deiodination of these chemicals in the liver. Taken together, this audit providesrecommendations for checking the thyroid organ in patients who require long haul lithium treatment. Preceding the initiationof lithium treatment, thyroid ultrasound ought to be performed, and the degrees of thyroid chemicals (fT3 and fT4), TSH, andantithyroid peroxidase and antithyroglobulin antibodies ought to be estimated. Assuming the patient shows ordinary thyroid function,TSH level estimation and thyroid ultrasound ought to be performed at 6-to year spans for long haul



Definition of clinical and subclinical hypothyroidism

It is an evaluated peculiarity with shifting levels of clinical seriousness and biochemical abnormalities.Plain hypothyroidism is set apart by unusually low free thyroxine and raised thyroid invigorating chemical (TSH). Besides, clear hypothyroidism is generally, however not

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 1 Jan-Feb 2024, pp: 1881-1886 www.ijprajournal.com ISSN: 2249-7781

dependably, related with side effects. In subclinical hypothyroidism, the basal serum TSH level is raised (> 5 µU/L) however free thyroxine is ordinary (FT4 file). The expression "subclinical" suggests that clinical side effects are missing;(18,19) in any case, a few examinations report the presence of substantial and neuropsychiatric side effects in subjects with raised TSH and typical FT4 level . It ought to be noticed that a large number of these side effects can be brought about by lithium alone as well as by gloom, subsequently on occasion making it challenging to recognize whether subclinical hypothyroidism is causing or adding to the presence of these side effects

MECHANISM OF LITHIUM-ASSOCIATED HYPOTHYROIDISM

Lithium has been accounted for to disrupt the amalgamation and arrival of thyroid chemicals through a few mechanisms. Hindrance of the thyroid organ's capacity to focus iodine and to combine sufficiently iodinated thyroglobulin has been depicted. Lithium disrupts thyroid chemical delivery, maybe through a settling impact on thyroid microtubules, or conceivably by diminishing adenylate cyclase responsiveness to TSH and stifling cyclic adenosine monophosphate (cAMP) production. A few examinations recommend the obstruction happens in cAMP sign transduction at a stage following cAMP production. Moreover, lithium hinders the transformation of T4 to T3 (the dynamic type of thyroid chemical) in the periphery and inside neurons. Patients might answer these thyroid suppressive impacts with a compensatory ascend in TSH, which is typically temporary. Nonetheless, a few patients keep up with raised TSH levels and advance to foster indications of clinical hypothyroidism. In any event, when thyroid capability tests stay inside typical cutoff points, lithium can advance goiter arrangement of changing clinical severity. The gamble of movement of lithium-related thyroid brokenness might be expanded in patients whose underlying thyroid capability is gently compromised and who are accordingly less ready to abrogate the thyroid suppressive impacts of lithium. This might incorporate those with a background marked by earlier thyroid infection or the individuals who have, at gauge, raised antithyroid antibodies (demonstrative of immune system thyroiditis). Numerous planned investigations have revealed that patients whose experimental outcomes are positive for antithyroid antibodies preceding lithium treatment have higher paces of lithium-related thyroid irregularities than their immunizer negative cohorts, and that these anomalies are probably going to be more severeor persistent or both. Be that as it may, patients whose experimental outcomes are positive for antithyroid antibodies preceding lithium treatment don't generally foster lithium-related thyroid dysfunction, and the improvement of thyroid irregularities has been accounted for at first in various immune response negative patients. Hence, the worth of starting counter acting agent levels to anticipate weakness to creating subclinical hypothyroidism stays sketchy. It has additionally been recommended that lithium capabilities as an immunostimulant that advances or worsens the improvement of immune system thyroiditis. Lithium has been displayed to influence markers of immunomodulation. In any case, since these progressions have not been connected to a genuine expansion in antithyroid neutralizer creation, they don't offer direct help for lithium's job as an immunostimulant. Most however not all, cross-sectional examinations show higher paces of thyroid antibodies in patients treated with lithium contrasted and those treated with different specialists. Lithium openness has been related with a critical ascent in immune response titers in those subjects who were neutralizer positive preceding treatment with lithium in many(15,16) yet not allimminent examinations. Resulting movement to thyroid brokenness happened in 2 of the studies(22,23) In any case, planned examinations have not shown fundamentally more prominent frequency paces of thyroid immunizer development in subjects presented to lithium contrasted and controls or with the general population.(26-30) furthermore, a few information recommend that the relationship among lithium and antithyroid antibodies might be a curio of the expanded commonness of thyroid immune system sickness in patients with emotional disorders.(31-34) In this manner, lithium presumably adds to immune system thyroid brokenness basically by means of worsening previous immune system thyroid illness as opposed to advancing the beginning of new disease.67 lithium prompted hypothyroidismAutoantibodies against thyroperoxidase (TPO-Stomach muscle) andagainst thyroglobulin (Tg-Abdominal muscle) assume a fundamental part in thepathogenesis of lithium-initiated hypothyroidism (LiI-Hypo).Probably, LiI-Hypo likewise influences various different factors such asinhibition of iodine take-up by the thyroid

International Journal of Pharmaceutical Research and Applications
Volume 9, Issue 1 Jan-Feb 2024, pp: 1881-1886 www.ijprajournal.com ISSN: 2249-7781

organ, iodine retention in the thyroid follicles, restraint of T4 and T3 delivery, and aninhibition of hepatic T4 to T3 transformation. LiI-Hypo might seem inthe initial not many months after the treatment and, surprisingly, following 15 years oftherapy (35). Different elements that can add to its development are orientation (ladies experience multiple times more frequently than men),geographical zone (regions with iodine inadequacy or proper iodine supplementation), and previous immune system diseases(41-45). A 2-year review examination by Johnson and Hawks in718 patients treated with lithium for BD showed hypothyroidism in roughly 14% of ladies matured 40 to 59 years, while theincidence among men was 4.5% (46). Comparable outcomes wereobtained by Kirov et al. who concentrated on 115 men and 159 womenwith BD; the gamble of LiI-Hypo frequency was higher in the groupof ladies matured north of 50 years (47). Lithium carbonate treatment isassociated with the gamble of creating LiI-Hypo, particularly inpatients with positive thyroid antibodies. If LiI-Hypo occurs, levothyroxine supplementation is suggested (25 - 75 µg/day),and lithium treatment can be proceeded.



II. CONCLUSION

Lithium being an effective and crucial medication in the management of full of affective disorders, concomitant thyroid brokenness stays appropriate clinical subject to address huge properties of patients treated with lithium grew clinically or radiologically affirmed hypothyroidism.

Benchmark and standard assessment of thyroid capability, thyroid cells utilizing thyroid ultrasonography and estimation of the titres of auto antibodies against thyroid peroxidase is recommended among patients earlier and during lithium treatment.

REFERENCES

[1]. Cade JF. Lithium salts in the treatment of psychotic excitement. Med J Austr 1949; 2:349-352.

[2]. Lange C, Amdisen A. Om periodize depressionstillstand ofderespatogenese: fore dragholdtiMedicinskSelskab den19. Januar 1886: Duo; 1886.

[3]. Mutschler E, Geisslinger G, Kroemer H, Ruth P, Schaefer-Korting M.FarmakologiaiToksykologia. Wroclaw,MedPharm Polska, 2010

[4]. Mueller-Oerlinghausen B, Lewitzka U. Lithium reducespathological aggression and suicidality: a mini-review.Neuropsychobiology 2010; 62: 43-49

[5]. Tondo L, Baldessarini RJ. Antisuicidal effects in mooddisorders: are they unique to lithium? Pharmacopsychiatry2018; 51: 177-188.
[6]. Jastrzebska H. Lithium therapy and thyroid disorders. PostNauk Med 2017; 12: 694-698
[7]. Kraszewska A, Abramowicz M, Chlopocka-Wozniak M,Sowinski J, Rybakowski J. The effect of lithium on thyroid196gland function in patients with bipolardisorder [in Polish].Psychiatric Pol 2014; 48: 694-698
[8]. Lazarus JH. Endocrine and Metabolic Effects of Lithium.Springer Science & Business Media, 1986.9
[9]. Grandjean E, Aubry J. Lithium: updated human knowledge using an evidence-based approach. Part II: clinical pharmacology and therapeutic monitoring. CNS Drugs. 2009;23(4):331–349. doi: 10.2165/00023210-200923040-00005. [PubMed] [CrossRef] [Google Scholar]
[10]. Chiu C, Chuang D. Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmocol Ther. 2010;128(2):281–304. doi: 10.1016/j.pharmthera.2010.07.006. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
[11]. Jope R. Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry. 1999;4(2):117–128. doi: 10.1038/sj.mp.4000494. [PubMed] [CrossRef] [Google Scholar]
[12]. Lazarus J. The effects of lithium therapy on thyroid and thyrotropin-releasing hormone. Thyroid. 1998;**8**(10):909–913. doi: 10.1089/thy.1998.8.909. [Pub Med][Crossref] [Google Scholar]
[13]. Lazarus J. Lithium and thyroid. Best Pract Res Clin Endocrinol Metab. 2009; **23:723**–733. doi: 10.1016/j.beem.2009.06.002.
[14]. Haggerty JJ, Garbutt JC, Evans DL, et al. Subclinical hypothyroidism: a review of neuro-psychiatric aspects. Intl J Psychiatry Med 1990;20: 193–208
[15]. Haggerty JJ, Prange AJ. Borderline hypothyroidism and depression. Annu Rev Med 1995;46:37–46
[16]. Monzani F, Del Guerra P, Caraccio N, et al. Subclinical hypothyroidism: neurobehavioral features and beneficial effect of L-thyroxine treatment. Clin Investing1993; 71:367–371 24
[17]. Bauer M, Whybrow P. Rapid cycling bipolar affective disorder, I: association with grade I hypothyroidism. Arch Gen Psychiatry 1990; 47:427–432 25.
[18]. Bauer M, Whybrow P. Rapid cycling bipolar affective disorder, II: treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study. Arch Gen Psychiatry 1990; 47:435–440 26.
[19]. Wenzel KW, Meinhold H, Raffenberg M, et al. Classification of hypothyroidism in evaluating patients after radioiodine therapy by serum cholesterol, T3-uptake, total T4, FT4-index, total T3, basal TSH, and TRH-test. Eur J Clin Invest 1974; 4:141–148 27.
[20]. Cooper DS, Halpern R, Wood LC, et al. L-Thyroxine therapy in subclinical hypothyroidism: a double-blind, placebo-controlled trial. Ann Intern Med 1984; 101:18–24
[21]. Johnson FN. Lithium Research and Therapy. AcademicPress, 1975
[22]. Kirov G, Tredget J, John R, Owen MJ, Lazarus JH. A cross-sectional and a prospective study of thyroid disorders inlithium-treated patients. J Affective Disord 2005; 87: 313-317.
[23]. Wilson R, McKlllop J, Crocket G, et al. The effect of lithium therapyon parameters thought to be involved in the development of autoimmune thyroid disease. ClinEndocrinol 1991; 34: 357-361.
[24]. Rappaport MR, Schmidt ME, Risinger R, et al. Effects of prolonged lithium exposure on the immune system of normal control subjects: serial serum soluble interleukin-2 receptor and antithyroid antibody measurements. Biol Psychiatry 1994; 35:761–766
[25]. Urabe M, Hershman J, Pang X, et al. Effect of lithium on function and growth of thyroid cells in vitro. Endocrinology 1991; 129:807–814
[26]. Bagchi N, Brown TR, Mack RE. Studies on the mechanism of inhibition of thyroid function by lithium. Biochim Biophys Acta 1978;542: 163–169
[27]. Spaulding W, Burrow GN, Bermudez F, et al. The inhibitory effect of nlithium on thyroid hormone release in both euthyroid and thyrotoxic patients. J Clin Endocrinol Metab1972; 35:905–911
[28]. Mori M, Tajima K, Oda Y, et al. Inhibitory effect of lithium on the release of thyroid

hormones from thyrotropin-stimulated mouse thyroids in a nperifusion system. Endocrinology 1989; 124:1365–1369

[29]. Havas ST, Hershman JM. Lithium and Thyroid Function: Thyroid and Trace Elements [videotape]. Braverman LE, Kohrle J, Eber O, et al, eds.Vienna, Austria: Blackwell; 1996

[30]. Whybrow PC. Sex differences in thyroid axis function: relevance to affective disorder and its treatment. Depression 1995; 3:33–42

[31]. Bhattacharyya B, Wolff J. Stabilization of microtubules by lithium ion. BiochemBiophys Res Commun1976; 73:383–390

[32]. Smigan L, Wahlin A, Jacobsson L, et al. Lithium therapy and thyroid function tests: a prospective study. Neuropsychobiology 1984; 11:39–43

[33]. Bocchetta A, Bernardi F, Burrai C, et al. The course of thyroid abnormalities during lithium treatment: a two-year follow-up study. Acta Psychiatr Scand 1992; 86:38–41

[34]. Myers DH, Carter BHB, Armond A, et al. A prospective study of the effect of lithium on thyroid function and on the prevalence of antithyroid antibodies. Psychol Med 1985; 15:55–61

[35]. Lervang HH, Pryds O, Ostergaard Kristensen HP. Thyroid dysfunction after delivery: incidence and clinical course. Acta Med Scand